Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma

Adamantinomatous craniopharyngioma (ACP) makes up between 6 and 8% of pediatric brain tumors and is the most common pediatric tumor arising in the sellar/suprasellar region of the brain. The 10-year survival for patients diagnosed with craniopharyngioma ranges between 64 and 92%, but complicating fa...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Sydney Grob, David M. Mirsky, Andrew M. Donson, Nathan Dahl, Nicholas K. Foreman, Lindsey M. Hoffman, Todd C. Hankinson, Jean M. Mulcahy Levy
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2019-08-01
Reeks:Frontiers in Oncology
Onderwerpen:
craniopharyngioma
IL-6
tocilizumab
pediatric
bevacizumab
Online toegang:https://www.frontiersin.org/article/10.3389/fonc.2019.00791/full
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items